AI MARKET SCANNING

Arbutus Biopharma Corporation

📅 Next Catalyst: Nov 11, 2026 (🌙 Close) 🏛️ NASDAQ 📁 Healthcare 🏭 Biotechnology
AVG HISTORICAL GAP -0.50%
MAX GAP RECORD +4.18%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $ABUS
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Nov 11, 2026 Earnings Release 2026-11-11 (UNDETERMINED) 🔮 UPCOMING 🔒
Aug 12, 2026 Earnings Release 2026-08-12 (BEFORE OPEN)
-1.71%
May 13, 2026 Earnings Release 2026-05-13 (BEFORE OPEN)
+4.18%
Mar 23, 2026 Earnings Release 2026-03-23 (BEFORE OPEN)
+2.83%
Nov 13, 2025 Earnings Release 2025-11-13 (BEFORE OPEN)
-1.24%
Aug 06, 2025 Earnings Release 2025-08-06 (BEFORE OPEN)
+0.88%
May 14, 2025 Earnings Release 2025-05-14 (BEFORE OPEN)
-1.25%
Mar 27, 2025 Earnings Release 2025-03-27 (BEFORE OPEN)
+0.00%

VOLATILITY & GAP BIAS

AVG GAP MOVE 2.1%
Bullish Gaps (3)
Bearish Gaps (7)
Neutral / Flat (3)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $ABUS

EXECUTIONS0 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
Radar monitoring: awaiting next setup.
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101,…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗